Celltrion Beats Q2 Guidance with 1.3 Trillion Won Revenue, Shares Fall 4.19%

According to Korea Exchange, Celltrion posted consolidated Q2 revenue of 1.3 trillion won and operating profit of 430 billion won on July 7, exceeding analyst consensus of 400.7 billion won by 7.31%. However, shares declined 4.19% to 175,900 won despite the better-than-expected results, reversing a 3.96% gain from the prior trading day.

Security analysts attributed the stock decline to sector rotation toward semiconductors, citing broader weakness in healthcare valuations. Korean Investment Securities cut its target price 6% to 260,000 won, adjusting EV/EBITDA multiples downward from 30x to 25x. Analysts expect new drug R&D progress, particularly in antibody-drug conjugate (ADC) candidates entering clinical trials, could serve as a catalyst for stock re-rating.